Signal12

“I am honored to lead Signal12 in its mission to transform the landscape of ocular health. The company’s pioneering technology and impressive clinical data for Pro-ocular make it a game-changer in treating dry eye disease. I am eager to leverage our team’s extensive experience and push forward with our Phase 3 trials. The eye health market is ripe for innovation, and Signal12 will play a crucial role in addressing unmet needs and improving the lives of millions affected by ocular conditions.” - Tom Mitro, President & CEO

Prescription eye drops for treating Dry Eye Disease have a slow onset of action, with the market leader taking 180 days to show effectiveness. Our patented, first-of-its-kind drug, Pro-ocular, which is applied to the forehead, provides noticeable relief in less than 14 days, offering a faster path to comfort. Learn more at the link below.

The global?dry eye?syndrome?market?size was valued at $7.02 billion in 2023 & is projected to grow from $7.49 billion in 2024 to $13 billion by 2032. ?? #DryEyeDisease #RaisingCapital #Phase3 #OcularHealth #ProOcular

Eye drop product recalls can happen due to contamination or harmful ingredients. Always stay informed by checking recall notices from reputable sources like the FDA. #EyeHealth #ProductSafety #DryEyeDisease

??Spotlight on Leadership?? Meet Tom Mitro, CEO of Signal12, who brings over 30 years of pharmaceutical industry expertise to our team. Before joining us, Tom served as President & COO of Aerie Pharmaceuticals, where he drove the company’s annual sales to over $100 million, leading to its successful acquisition by Alcon. His leadership prowess was also evident at ISTA Pharmaceuticals, where he initiated and led commercialization efforts, growing its sales to over $165 million annually. With 24 years of experience at Allergan in multiple leadership roles, Tom's track record speaks for itself. Under Tom’s guidance, Signal12 is poised for groundbreaking achievements in ocular health for the treatment of dry eye disease. We’re excited to embark on this journey of innovation and growth with such an accomplished leader at the helm. #Leadership #OcularHealth #Innovation #Pharmaceuticals #Healthcare #Signal12 #DryEyeDisease

Screen Time and Dry Eye: Excessive screen time is a leading cause of dry eye disease. The 20-20-20 rule (taking a 20-second break every 20 minutes to look at something 20 feet away) can help reduce strain. #DigitalEyeStrain #HealthyEyes

Did you know that certain medications, such as antihistamines and antidepressants, can contribute to dry eye? Discuss options with your healthcare provider if you experience symptoms. #MedicationAwareness #DryEyeDisease ??

Autoimmune diseases can lead to dry eye. Stay vigilant about your eye health. #AutoimmuneAwareness #DryEyeDisease

?????? “Dry eye” is not a single disease or diagnosis. “Dry eye” is commonly used to refer to the clinical signs and/or the symptoms of many diseases and conditions, each with its own separate underlying causes, regardless of severity. Sometimes these diseases or conditions remain undiagnosed for years because symptoms are mild and can be lumped under the convenient heading of “dry eye”. The ocular surface diseases that fall in this “dry eye bucket” may involve the moisture-secreting (lacrimal) glands above the eye, the oil-secreting (meibomian) glands in our eyelids, our blink function, our tear drainage (nasolacrimal) system, or the underside of the eyelids, or the entire surface of the eye. They may also involve damage to the nerves in the surface of the eye (cornea), resulting in intense chronic pain even in the absence of any obvious sign of disease at all. There may be allergies or inflammatory conditions or dermatological conditions involved.?#dryeyedisease

Did you know that eye drops bypass some of the body’s natural defenses, posing a heightened risk of harm to users? Our breakthrough topical gel product, Pro-ocular ?, treats dry eye disease without the hassle of eye drop instillation. Learn how at www.signal12inc.com.